These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894 [Abstract] [Full Text] [Related]
3. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. Dittrich E, Schillinger M, Sunder-Plassmann G, Hörl WH, Vychytil A. Perit Dial Int; 2002 Feb; 22(1):60-6. PubMed ID: 11929146 [Abstract] [Full Text] [Related]
4. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE, Peat N, Porter C, Morgan AG. Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972 [Abstract] [Full Text] [Related]
5. [Iron replacement in hemodialysis patients with a normal serum ferritin level]. Riedel MK, Morgenstern T. Dtsch Med Wochenschr; 2004 Sep 03; 129(36):1849-53. PubMed ID: 15368155 [Abstract] [Full Text] [Related]
6. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Chen YC, Hung SC, Tarng DC. Am J Kidney Dis; 2006 Jun 03; 47(6):1036-44. PubMed ID: 16731299 [Abstract] [Full Text] [Related]
7. Influence of intravenous iron therapy on novel markers of iron deficiency. Chinnappa S, Bhandari S. Int J Artif Organs; 2010 May 03; 33(5):297-301. PubMed ID: 20593351 [Abstract] [Full Text] [Related]
8. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, Ambühl PM, Lüthi L, Wüthrich RP. Nephrol Dial Transplant; 2006 Oct 03; 21(10):2841-5. PubMed ID: 16891647 [Abstract] [Full Text] [Related]
9. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients. Baldus M, Salopek S, Möller M, Schliesser J, Klooker P, Reddig J, Gansert U, Brass H. Nephrol Dial Transplant; 1996 Mar 03; 11(3):486-91. PubMed ID: 8710158 [Abstract] [Full Text] [Related]
10. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients]. Ogi M, Horiuchi T, Abe R, Wakabayashi M, Wakabayashi T. Nihon Jinzo Gakkai Shi; 2004 Mar 03; 46(8):804-9. PubMed ID: 15645737 [Abstract] [Full Text] [Related]
11. [Indications and practical management of parenteral iron therapy]. Kosch M, Schaefer RM. Wien Klin Wochenschr; 2003 Jun 24; 115(11):380-4. PubMed ID: 12879735 [Abstract] [Full Text] [Related]
12. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Kulnigg S, Teischinger L, Dejaco C, Waldhör T, Gasche C. Am J Gastroenterol; 2009 Jun 24; 104(6):1460-7. PubMed ID: 19491860 [Abstract] [Full Text] [Related]
13. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Sepandj F, Jindal K, West M, Hirsch D. Nephrol Dial Transplant; 1996 Feb 24; 11(2):319-22. PubMed ID: 8671786 [Abstract] [Full Text] [Related]
14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. Pollak VE, Lorch JA, Shukla R, Satwah S. BMC Nephrol; 2009 Feb 26; 10():6. PubMed ID: 19245700 [Abstract] [Full Text] [Related]
15. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Yong K, Kairaitis L. Nephrology (Carlton); 2010 Apr 26; 15(3):288-93. PubMed ID: 20470296 [Abstract] [Full Text] [Related]
16. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Am J Kidney Dis; 1996 Feb 26; 27(2):234-8. PubMed ID: 8659499 [Abstract] [Full Text] [Related]
17. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial. Giordano A, Arrigo G, Lavarda F, Colasanti G, Petrini C. J Nephrol; 2005 Feb 26; 18(2):181-7. PubMed ID: 15931646 [Abstract] [Full Text] [Related]
18. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Trivedi HS, Brooks BJ. Am J Nephrol; 2003 Feb 26; 23(2):78-85. PubMed ID: 12481145 [Abstract] [Full Text] [Related]
19. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Geisser P, Rumyantsev V. Arzneimittelforschung; 2010 Feb 26; 60(6a):373-85. PubMed ID: 20648929 [Abstract] [Full Text] [Related]
20. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, Gleiss A, Hörl WH, Sunder-Plassmann G. Clin J Am Soc Nephrol; 2021 Oct 26; 16(10):1512-1521. PubMed ID: 34470831 [Abstract] [Full Text] [Related] Page: [Next] [New Search]